- ►annals.org [PDF] W Lim, F Dentali, JW Eikelboom, MA Crowther - Annals of internal medicine, 2006 - Am Coll Physicians Purpose: To compare levels of anti-Xa heparin and risk for major bleeding in
LMWH-treated patients with a creatinine clearance of 30 mL/min or less versus
those with a creatinine clearance greater than 30 mL/min by using standard ... Cited by 102 - Related articles - BL Direct - All 5 versions
I MAHE, M AGHASSARIAN, L DROUET, C … - Thrombosis and haemostasis, 2007 - cat.inist.fr Low-molecular-weight heparins(LMWHs) accumulate in patients with impaired renal
function. As this accumulation depends on heparin chain length and subsequent
reticulo-endothelial/renal elimination, LMWHs might have different ... Cited by 21 - Related articles - BL Direct - All 4 versions
- ►critcaremed.com CG Rabbat, DJ Cook, MA Crowther, E … - Journal of critical care, 2005 - Elsevier In this prospective single-center cohort study, we enrolled patients 18 years or
older, expected to stay 72 hours or longer, and with a creatinine clearance 30
mL/min or higher at intensive care unit admission. We administered 5000 IU ... Cited by 31 - Related articles - All 5 versions
JS Hulot, G Montalescot, P Lechat, JP Collet, … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Methods: We conducted a population pharmacokinetic analysis using anti-Xa
activities measured in 532 patients (normal renal function in 34%, mild renal
impairment in 36%, moderate renal impairment in 20%, and severe renal ... Cited by 34 - Related articles - All 4 versions
SL Chow, K Zammit, K West, MA … - The Journal of Clinical Pharmacology, 2003 - jcp.sagepub.com Enoxaparin is a low molecular weight heparin (LMWH) that has been shown to be
effective in deep vein thrombosis, pulmonary embolism, and unstable angina.
Because renal function plays an important role in the clearance of LMWH, ... Cited by 66 - Related articles - BL Direct - All 6 versions
V Siguret, E Pautas, M Fevrier, C Wipff, B … - Thrombosis and haemostasis, 2000 - ncbi.nlm.nih.gov Since low molecular weight heparins (LMWH) are partly eliminated by renal
excretion, their pharmacodynamic profile may be modified in very elderly
patients with age-related renal impairment. The aim of this prospective ... Cited by 83 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org G Montalescot, JP Collet, ML Tanguy, A Ankri … - Circulation, 2004 - Am Heart Assoc Methods and Results— In all, 803 consecutive patients with UA/NSTEMI were
treated with subcutaneous enoxaparin and were followed up for 30 days. The
recommended dose of enoxaparin of 1 mg/kg BID was used throughout the ... Cited by 68 - Related articles - BL Direct - All 8 versions
SA Spinler, SM Inverso, M Cohen, SG … - American Heart Journal, 2003 - Elsevier When compared with UFH, enoxaparin reduced the rate of the primary end point in
patients who were obese (14.3% vs 18.0%, P = .05), patients who were not obese
(16.1% vs 19.2%, P <.01), and patients without severe renal impairment ... Cited by 67 - Related articles - All 9 versions
- ►haematologica.com [PDF] E Tincani, C Mannucci, B Casolari, F Turrini, … - Haematologica, 2006 - haematologica.com The American College of Chest Physicians (ACCP) Consensus Conference on Anti-
thrombotic Therapy strongly recom- mends the use of either low-dose unfraction-
ated heparin or low-molecular-weight heparins (LMWH) for the prevention of ... Cited by 15 - Related articles - All 11 versions
GJCM Sanderink, CG Guimart, ML Ozoux, NU … - Thrombosis research, 2002 - Elsevier The pharmacokinetics of the low-molecular-weight heparin enoxaparin were
evaluated in 12 healthy volunteers and 36 patients with mild, moderate or severe
renal impairment. Enoxaparin was administered once daily by subcutaneous ... Cited by 109 - Related articles - All 7 versions
